Blog
Who pays to create new medicines?
Does government spending on drug development justify government price controls on medicines? Not when the private sector spends $102 billion on clinical R&D and the NIH spends less than $3 billion.
Read MoreLaura Gunter: Biotech policies should protect patients, innovation
Laura Gunter: Biotech policies should protect patients, innovation The ongoing response to the COVID-19 pandemic has highlighted the critical role of the North Carolina life sciences industry in battling our most serious public health threats. When faced with the threat of COVID-19, biotechnology companies — many based right here in North Carolina — answered the…
Read MorePharmaceutical Prescribing Labels: An Enormous Opportunity to Eliminate Pointless Paper Waste in the United States
Pharmaceutical Prescribing Labels: An Enormous Opportunity to Eliminate Pointless Paper Waste in the United States This post originally appeared on the website of the Environmental Paper Network. A serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and…
Read MoreBIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients
BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and…
Read MoreBIO: What happened with the Orphan Drug Tax Credit
BIO: What happened with the Orphan Drug Tax Credit During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s…
Read MoreBIO’s fall Congressional preview
The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.
Read MoreBIO: Where things stand with TRIPS waiver
BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and…
Read MoreBIO: How the PASTEUR Act would support antibiotic R&D
BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it matters. Antimicrobial resistance is a big problem. AMR occurs when bacteria, viruses, fungi and…
Read MoreGovernment price fixing for U.S. medicines will cost lives, jobs, innovation
Legislation like H.R. 3 that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter.
Read MoreVaccine patent waiver breaks faith with American companies, stifles innovation
Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the…
Read More